Armata Pharma Reports Officer/Director Changes & Compensation
Ticker: ARMP · Form: 8-K · Filed: Aug 15, 2024 · CIK: 921114
| Field | Detail |
|---|---|
| Company | Armata Pharmaceuticals, INC. (ARMP) |
| Form Type | 8-K |
| Filed Date | Aug 15, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $350,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation, filing
TL;DR
Armata Pharma's 8-K details exec/board changes and pay as of July 31.
AI Summary
Armata Pharmaceuticals, Inc. filed an 8-K on August 15, 2024, reporting events as of July 31, 2024. The filing primarily concerns the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for these officers. It also includes financial statements and exhibits.
Why It Matters
Changes in a company's board and executive team, along with details on their compensation, can signal shifts in strategy or financial health that are important for investors to monitor.
Risk Assessment
Risk Level: medium — Changes in executive and board composition, especially when coupled with compensatory arrangements, can indicate internal shifts that may impact future performance.
Key Players & Entities
- Armata Pharmaceuticals, Inc. (company) — Registrant
- July 31, 2024 (date) — Earliest event reported
- August 15, 2024 (date) — Filing date
FAQ
What specific officer or director positions were affected by the events reported on July 31, 2024?
The filing indicates changes related to the departure of directors or certain officers, election of directors, and appointment of certain officers, but does not specify the exact positions in the provided text.
Are the compensatory arrangements for the newly appointed or departing officers detailed in this filing?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item information, suggesting these details are included, though not explicitly listed in the provided excerpt.
What is the primary reason for filing this 8-K report?
The primary reasons for filing this 8-K are to report the departure of directors or certain officers, the election of directors, the appointment of certain officers, and related compensatory arrangements, as well as to file financial statements and exhibits.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on July 31, 2024.
What is Armata Pharmaceuticals, Inc.'s state of incorporation?
Armata Pharmaceuticals, Inc. is incorporated in Washington (WA).
Filing Stats: 1,238 words · 5 min read · ~4 pages · Grade level 11.8 · Accepted 2024-08-15 17:00:13
Key Financial Figures
- $350,000 — es for an initial annual base salary of $350,000, with a target annual bonus opportunity
Filing Documents
- tm2421653d1_8k.htm (8-K) — 33KB
- tm2421653d1_ex10-1.htm (EX-10.1) — 35KB
- tm2421653d1_ex99-1.htm (EX-99.1) — 11KB
- tm2421653d1_ex10-1img001.jpg (GRAPHIC) — 23KB
- tm2421653d1_ex99-1img01.jpg (GRAPHIC) — 2KB
- 0001104659-24-090153.txt ( ) — 300KB
- armp-20240731.xsd (EX-101.SCH) — 3KB
- armp-20240731_lab.xml (EX-101.LAB) — 33KB
- armp-20240731_pre.xml (EX-101.PRE) — 22KB
- tm2421653d1_8k_htm.xml (XML) — 3KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) and (c) On July 31, 2024, Armata Pharmaceuticals, Inc. (the " Company ") entered into an employment letter agreement (the " Agreement ") with David House, pursuant to which he has agreed to serve as the Company's Senior Vice President, Finance, effective August 16, 2024 (the " Effective Date "). On August 15, 2024, the Company announced Mr. House's appointment as Senior Vice President, Finance in the press release furnished hereto as Exhibit 99.1. The Company delayed the filing of this Current Report on Form 8-K until the date on which the Company made a public announcement of such appointment pursuant to the instruction to Item 5.02(c) of Form 8-K. Before joining the Company, Mr. House, age 40, served as Corporate Controller and Vice President of Accounting at ZO Skin Health, Inc., a multi-channel physician-dispensed skincare company, from October 2018 to May 2024. At ZO Skin Health, he led global accounting operations, managed financial reporting, and played a crucial role in the company's acquisition by Blackstone. He also established international subsidiaries and oversaw financial integration for mergers and acquisitions. Mr. House's experience includes similar financial leadership roles at Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, and Avid Bioservices, Inc. (CDMO), a contract development and manufacturing organization where he served as Controller and was responsible for implementing ASC 606, managing technical accounting, and conducting Securities and Exchange Commission (the " SEC ") reporting. His career also includes roles at Viant, Inc. (DSP), Sourcing Solutions, LLC, and Apria Healthcare (APR), where he held various accounting and financial management positions. In the early stages of his career, Mr. House worked as a Senior Auditor at Windes, a public acco
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press release, dated August 15, 2024. 10.1 Employment Letter Agreement, dated July 31, 2024, by and between Armata Pharmaceuticals, Inc. and David House. 104 Cover Page Interactive Data File (embedded within XBRL document) - 3 -
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 15, 2024 Armata Pharmaceuticals, Inc. By: /s/ Deborah L. Birx Name: Deborah L. Birx, M.D. Title: Chief Executive Officer (Principal Executive Officer) - 4 -